Inactive Instrument

Ophthotech Corp Stock price Nasdaq

Equities

US6837451037

Biotechnology & Medical Research

Dynamic Chart

Latest transcript on Ophthotech Corp

Managers TitleAgeSince
Chief Executive Officer 68 13-06-30
President 58 23-07-10
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 68 13-06-30
President 58 23-07-10
More insiders
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
More about the company
  1. Stock
  2. Equities
  3. Stock IVERIC bio, Inc.
  4. Stock Ophthotech Corp - Nasdaq